Skip to Content

Clinical Trials


Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

Salvage Programs

Minimal Residual Diesease

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

FLT3 Mutated Only

IDH Mutated only

Frontline AML Post-Hypomethylating Therapy for MDS

Secondary Leukemia


Mixed Phenotype Acute Leukemia

  • Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids (2013-0073)



Supportive Care for AML

Maintenance (Patients in CR)

Observational Studies

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

RAS Mutated

IDH 1/2 Mutations

Post Hypomethylating Agents:

Low Risk/IPSS Int-1

IPSS int-2 or high

MDS 20% Blasts

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

Mimimal Residual Disease

Prior Therapy

Richter’s Transformation   

  • Oral Selinexor (2014-0601)
  •  Moxetumomab Pasudotox (2013-0302)                       

Other Studies

Chronic Myelogenous Leukemia (CML)

Chronic phase

Accelerated Phase

Blastic Phase

Imatinib failures with T315l mutations (any stage)

Minimal Residual Disease

Treatment Discontinuation

Supportive Care

Other Studies

Roll-over Studies

Myeloproliferative Diseases



Hemophagocytic Lymphohistiocytosis

  • Alemtuzumab + Etoposide & Dexamethasone (2014-0989)

Leukemia Insights

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center